ACE inhibitors to block MMP-9 activity: New functions for old inhibitors

Journal of Molecular and Cellular Cardiology

Volumn 43, Issue 6, 2007, Pages 664-666

  Jin, Yufang ^a   Han, Hai Chao ^a   Lindsey, Merry L ^b  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Editorial; Matrix metalloproteinase 9

Indexed keywords

COLLAGEN TYPE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRONECTIN; GELATINASE B; IMIDAPRIL; LAMININ; LISINOPRIL; LOSARTAN; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

CELL FUNCTION; DRUG BINDING; DRUG INHIBITION; DRUG MECHANISM; EDITORIAL; ENZYME ACTIVITY; GENE EXPRESSION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; MYOCARDIAL INFARCTION; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 36448992977     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2007.09.002     Document Type: Editorial

References (22)

1. Pfeffer M.A., Pfeffer J.M., Steinberg C., and Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 72 (1985) 406-412
2. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992) 669-677
3. Patten R.D., Aronovitz M.J., Einstein M., Lambert M., Pandian N.G., Mendelsohn M.E., et al. Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse. Clin Sci (Lond) 104 (2003) 109-118
4. Yoshiyama M., Nakamura Y., Omura T., Izumi Y., Matsumoto R., Oda S., et al. Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice. Heart 91 (2005) 1080-1085
5. Yamamoto D., Takai S., Jin S., Tanaka K., and Miyazaki M. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol. 43 (2007) 670-676
6. Azevedo C.F., Cheng S., and Lima J.A. Cardiac imaging to identify patients at risk for developing heart failure after myocardial infarction. Curr Heart Fail Rep 2 (2005) 183-188
7. Diekmann O., and Tschesche H. Degradation of kinins, angiotensins and substance P by polymorphonuclear matrix metalloproteinases MMP 8 and MMP 9. Braz J Med Biol Res 27 (1994) 1865-1876
8. Lindsey M.L. Novel strategies to delineate matrix metalloproteinase (MMP)-substrate relationships and identify targets to block MMP activity. Mini Rev Med Chem 6 (2006) 1243-1248
9. Lindsey M.L. MMP induction and inhibition in myocardial infarction. Heart Fail Rev 9 (2004) 7-19
10. Olson M.W., Gervasi D.C., Mobashery S., and Fridman R. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem 272 (1997) 29975-29983
11. Lindsey M.L., Mann D.L., Entman M.L., and Spinale F.G. Extracellular matrix remodeling following myocardial injury. Ann Med 35 (2003) 316-326
12. Lindsey M., Wedin K., Brown M.D., Keller C., Evans A.J., Smolen J., et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 103 (2001) 2181-2187
13. Rohde L.E., Ducharme A., Arroyo L.H., Aikawa M., Sukhova G.H., Lopez-Anaya A., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 15 (1999) 3063-3070
14. Lindsey M.L., Escobar G.P., Dobrucki L.W., Goshorn D.K., Bouges S., Mingoia J.T., et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol 290 (2006) H232-H239
15. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003) 1579-1585
16. Yamamoto D., Takai S., and Miyazaki M. Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site. Biochem Biophys Res Commun 354 (2007) 981-984
17. Jin D., Takai S., Yamada M., Sakaguchi M., Yao Y., and Miyazaki M. Possible roles of cardiac chymase after myocardial infarction in hamster hearts. Jpn J Pharmacol 86 (2001) 203-214
18. Matsumoto T., Wada A., Tsutamoto T., Ohnishi M., Isono T., and Kinoshita M. Chymase Inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 107 (2003) 2555-2558
19. Akasu M., Urata H., Kinoshita A., Sasaguri M., Ideishi M., and Arakawa K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 32 (1998) 514-520
20. Muller D.N., Fischli W., Clozel J.-.P., Hilgers K.F., Bohlender J., Menard J., et al. Local angiotensin II generation in the rat heart. Circ Res 82 (1998) 13-20
21. Dewald O., Ren G., Duerr G.D., Zoerlein M., Klemm C., Gersch C., et al. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol 164 (2004) 665-677
22. Tchougounova E., Lundequist A., Fajardo I., Winberg J.-.O., Abrink M., and Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 280 (2005) 9291-9296